Indacaterol

Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder) . Indacaterol can also be used in cardiovascular disease research[1][2].

Product Specifications

CAS Number

[312753-06-3]

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Endocrinology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/indacaterol.html

Purity

99.98

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

OC1=CC=C([C@@H](O)CNC2CC(C=C(CC)C(CC)=C3)=C3C2)C4=C1NC(C=C4)=O

Molecular Formula

C24H28N2O3

Molecular Weight

392.49

Precautions

H302, H312, H332

References & Citations

[1]Lee SU, et al. Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation. Mol Cells. 2014 Aug;37 (8) :585-91. |[2]Calzetta L, et al. Effects of the new ultra-long-acting β2-AR agonist indacaterol in chronic treatment alone or in combination with the β1-AR blocker metoprolol on cardiac remodelling. 2015.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

β adrenergic receptor

Citation 01

BioRxiv. 2025 May 29:2025.05.28.656715.|Drug Test Anal. 2021 Feb;13 (2) :283-298.|J Chromatogr A. 2024 Feb 22:1717:464696.|J Neuroimmunol. 2019 Jul 15:332:37-48.|Pharmaceutics. 2020 Feb 11;12 (2) :145.